TVRD Stock — Tvardi Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.63

Market cap

$21.7M

Cash

$15.8M

Enterprise value

$5.9M

Balance sheet

Cash	$15.8M
Debt	$0.0M
Net cash	$15.8M
Enterprise value	$5.9M
Basic shares	9.4M shares
Fully diluted shares	14.9M shares
Fully diluted market cap	$24.2M
Cash per share	$1.68

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TVRD daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	TTI-101	Phase 1/2	Hepatocellular Carcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

TTI-101

Phase 2 · Active Modality: oral small molecule

Target STAT3

Partnerships Baylor College of Medicine: exclusive worldwide sublicenseable license to STAT3 inhibitor patents/technology (BCM First Agreement; Second Agreement for anaphylaxis terminated Apr 2026 as immaterial).

Indications

Hepatocellular carcinoma (HCC) (Phase 2)
Idiopathic pulmonary fibrosis (IPF) (Phase 2)

Catalysts

— Q4 2026

Status note First-generation direct STAT3 inhibitor in Phase 1b/2 (REVERT LIVER CANCER) in HCC. Phase 2 in IPF reported Oct 2025 did not meet its goals; company continues evaluating results for potential future development decisions.

TTI-109

Phase 1 · Active Modality: oral small molecule (phosphate prodrug)

Target STAT3

Partnerships Baylor College of Medicine: exclusive worldwide sublicenseable license to STAT3 inhibitor patents/technology.

Indications

Ulcerative colitis (UC) (Stage not disclosed)

Status note Phosphate prodrug of TTI-101 designed for enhanced systemic delivery and tolerability. IND submitted Jun 2025; Phase 1 in healthy volunteers with topline data reported Jul 2026. UC selected as initial disease indication Jul 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TTI-101
Lead indication	Hepatocellular Carcinoma
Lead phase	Phase 1/2
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05440708	Phase 1/2	Recruiting	Sponsor	Tvardi Therapeutics, Incorporated	—	Hepatocellular Carcinoma	—
NCT06141031	Phase 1	Recruiting	Collaborator	Washington University School of Medicine	—	Pancreatic Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Tvardi Therapeutics, Incorporated on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

TVRD — Tvardi Therapeutics Inc.